REMARKS

Applicants wish to clarify that claims 1 and 4-7 are under active consideration while claims 2, 3 and 8-16 have been canceled (see p. 4 of the Response filed January 20, 2002). Reconsideration and withdrawal of the rejections set forth in the Office Action dated July 26, 2005 are respectfully requested. A separate petition for a 2-month extension of time accompanies this amendment.

I. <u>Amendments</u>

-1

Claim 1 is amended to state the added peptidic sequence is SEQ ID NO:4. Support for this amendment may be found in the claims as originally filed, as well as Figures 1-5, and Table 1 at page 16 of the Specification. Applicants assert that no new matter has been added by way of this amendment.

II. Interview Summary in accord with MPEP § 713.04

Applicants thank the Examiner and her Supervisor for granting a telephonic interview regarding the above-referenced application on November 22, 2005. The participants were Examiner DiBrino (USPTO), and Gina Freschi (Applicants' representative). This written summary is submitted in accordance with MPEP §713.04.

- 1. No exhibits were shown or discussed.
- 2. Filing a request for continued examination ("RCE") was generally discussed.
- 3. Requirements for overcoming the outstanding obviousness rejection were generally discussed as well as the nature of the rejection.
 - 4. The election of species was generally discussed.
 - 5. An agreement was not reached.

III. Conclusion

In view of the foregoing, Applicants submit that the claims pending in the application are in condition for allowance. A Notice of Allowance is therefore respectfully requested.

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4300.

Respectfully submitted,

Arna C. Lexeli,

Gina C. Freschi

Registration No. 52,062

Date: Ocember 23,2005

Correspondence Address:

Customer No. 22918 (650) 838-4341

(000) 000 101